Amgen Inc. (NASDAQ:AMGN) Shares Bought by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 88,798 shares of the medical research company's stock after buying an additional 8,494 shares during the quarter. UniSuper Management Pty Ltd's holdings in Amgen were worth $23,144,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AMGN. Charles Schwab Investment Management Inc. increased its holdings in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after purchasing an additional 2,672,975 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Amgen in the fourth quarter valued at $401,913,000. Van ECK Associates Corp increased its holdings in Amgen by 263.8% in the fourth quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company's stock valued at $270,699,000 after buying an additional 753,147 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Amgen by 40.7% in the fourth quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company's stock worth $609,526,000 after acquiring an additional 676,598 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Amgen by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock worth $1,657,183,000 after acquiring an additional 538,545 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on AMGN shares. UBS Group reaffirmed a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an "outperform" rating and set a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Piper Sandler lifted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Bank of America upped their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $314.04.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 over the last 90 days. Corporate insiders own 0.69% of the company's stock.

Amgen Trading Up 1.2 %

NASDAQ:AMGN traded up $3.62 during trading hours on Monday, reaching $310.57. 1,017,424 shares of the stock were exchanged, compared to its average volume of 3,099,781. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business has a 50-day moving average of $301.08 and a two-hundred day moving average of $297.94. The company has a market capitalization of $166.84 billion, a price-to-earnings ratio of 41.13, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.07%. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.